NephroPlus reported strong Q1 FY27 results with a 23.7% rise in revenue, boosted by its growing international clinic network. While profit and margins improved significantly, investors are watching the company's ability to manage costs and scale new international operations efficiently.
Nephrocare Health Services, known as NephroPlus, has started the 2027 fiscal year with strong growth, reporting a 23.7% year-on-year increase in first-quarter revenue to ₹281.8 crore. Following these results, brokerage firm Nomura has maintained a 'Buy' rating on the stock and raised its target price to ₹780. This optimism is largely tied to the company's successful expansion into international markets.
Growth Driven by International Expansion
The company's international operations have become a primary engine for growth. International markets now contribute 44% of total revenue, a significant jump from 12% in fiscal year 2023. During the first quarter, the company served over 1 million total treatments, representing a 13.3% increase. Additionally, the amount earned per treatment rose by 9.2% to ₹2,733. The company currently operates 550 clinics across five countries, including a recent expansion milestone of 51 clinics in the Philippines.
Profitability and Financial Performance
Profitability metrics also showed improvement. Adjusted profit after tax surged 41.7% year-on-year to ₹36.8 crore. The company's operating profit margin, or EBITDA margin, expanded by 120 basis points to 23.1%. This indicates that the company is effectively managing its core business costs even while aggressively expanding its footprint. Nomura has adjusted its valuation target, moving to 21.5 times the expected EV/EBITDA for September 2028, reflecting the company’s improved operational scale.
Risks and Execution Challenges
While the growth figures are positive, investors should consider the challenges inherent in the company’s business model. NephroPlus operates in an asset-heavy sector, which means it requires significant capital to set up and maintain clinics. The company reported a Rs 36 million loss from its joint venture in Saudi Arabia during the quarter. Such losses are common in the early stages of entering new geographical markets but remain a point for investors to monitor, as they can impact overall profitability.
Additionally, the company faces execution risks. The success of these new facilities depends on how quickly they can reach full capacity, often referred to as the occupancy ramp-up. If new clinics take longer than expected to become profitable, it could put pressure on margins. Other factors include potential regulatory changes regarding dialysis pricing or insurance reimbursement norms, as well as the rising cost of hiring and retaining specialized renal nurses and clinical staff. Nomura notes that the stock may continue to trade at a discount to other diagnostic and specialty healthcare peers due to its specific operational model and heavy international exposure.
The key monitorables for investors in the coming quarters will be the speed at which new international clinics reach their intended capacity, the trend in talent costs, and progress in reducing losses from the Saudi Arabian joint venture.